CV Sciences, Inc. (CVSI)
| Market Cap | 6.06M |
| Revenue (ttm) | 13.79M |
| Net Income (ttm) | -958.00K |
| Shares Out | 197.33M |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 165,033 |
| Average Volume | 764,451 |
| Open | 0.0290 |
| Previous Close | 0.0323 |
| Day's Range | 0.0290 - 0.0339 |
| 52-Week Range | 0.0230 - 0.1000 |
| Beta | 0.51 |
| RSI | 41.85 |
| Earnings Date | May 14, 2026 |
About CV Sciences
CV Sciences, Inc. engages in the development, manufacture, marketing, and sale of herbal supplements, hemp-based cannabidiol (CBD), and plant-based food products in North America. It offers its products under the PlusCBD, PlusCBD Pet, PlusHLTH, Cultured Foods, and Lunar Fox brand names in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, select distributors, brick and mortar retailers, and select e-tailers. The company was formerly known as CannaVest Corp. and changed it... [Read more]
Full Company ProfileFinancial Performance
In 2025, CV Sciences's revenue was $13.79 million, a decrease of -12.20% compared to the previous year's $15.71 million. Losses were -$958,000, -59.98% less than in 2024.
Financial StatementsNews
CV Sciences Earnings Call Transcript: Q4 2025
Revenue declined to $13.8M in 2025, but gross margin rose to 49% and cost reductions drove positive Q4 adjusted EBITDA. New product launches, acquisitions, and regulatory changes position the company for growth and improved cash flow in 2026.
CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results
SAN DIEGO, CA / ACCESS Newswire / March 26, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extra...
CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026
SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extra...
CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth
SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in proven, sc...
CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness
With 20g of clean protein, 5g of creatine, and LactoSpore® probiotics, Empowr supports everyday strength, mental energy and digestive balance without dairy or added sugar. Simple, functional nutrition...
CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD
SAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp ex...
CV Sciences Earnings Call Transcript: Q3 2025
Q3 2025 revenue declined 16% year-over-year to $3.3 million, with gross margin improving to 48.5%. Regulatory uncertainty and out-of-stock issues impacted sales, but cost controls and acquisition integration position the company for positive cash flow and growth in 2026.
CV Sciences, Inc. Reports Third Quarter 2025 Financial Results
SAN DIEGO, CA / ACCESS Newswire / November 13, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp ex...
CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025
SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 10, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in...
CV Sciences Launches Ignite: A Men's Performance Formula for Vitality, Recovery, Libido & Focus
Ignite delivers a powerful blend of proven botanicals along with our award-winning CBD, designed to help men stay strong, sharp, and ready-at work, in the gym, and beyond. SAN DIEGO, CALIFORNIA / ACCE...
CV Sciences Earnings Call Transcript: Q2 2025
Q2 2025 saw flat sequential revenue at $3.6M, a record 50.9% gross margin, and first positive adjusted EBITDA since 2019. Cost efficiency, new product launches, and M&A integration drove margin gains despite regulatory headwinds.
CV Sciences, Inc. Reports Second Quarter 2025 Financial Results
SAN DIEGO, CA / ACCESS Newswire / August 13, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extr...
CV Sciences, Inc. To Announce Second Quarter 2025 Results On August 13, 2025
SAN DIEGO, CALIFORNIA / ACCESS Newswire / August 8, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in he...
CV Sciences, Inc. Applauds Governor Abbot's Veto of Senate Bill 3
SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 23, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hem...
CV Sciences, Inc. Reports First Quarter 2025 Financial Results
SAN DIEGO, CA / ACCESS Newswire / May 14, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extract...
CV Sciences Earnings Call Transcript: Q1 2025
Q1 2025 saw revenue of $3.6M and a 46% gross margin, with cost savings and new product launches offsetting regulatory headwinds. In-sourcing manufacturing and M&A are expected to drive margin and cash flow improvements in the second half of 2025.
CV Sciences, Inc. to Announce First Quarter 2025 Results on May 14, 2025
SAN DIEGO, CA / ACCESS Newswire / May 9, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts...
CV Sciences Earnings Call Transcript: Q4 2024
Revenue for 2024 was $15.7 million, with improved gross margin and reduced operating expenses despite a challenging market. New product launches and acquisitions drove growth, while cost efficiency and cash management remain priorities.
CV Sciences, Inc. Reports Fiscal Year-End 2024 Financial Results
SAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extra...
CV Sciences Unveils Lunar Fox Food Co., an All-New Line of Plant-Based Foods
The innovative product line offers a unique choice of plant-based, 100% natural alternatives to the foods everyone loves. SAN DIEGO, CA / ACCESS Newswire / March 26, 2025 / CV Sciences, Inc. (OTCQB:CV...
CV Sciences, Inc. To Announce Year End and Fourth Quarter 2024 Results On March 27, 2025
SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 20, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in he...
CV Sciences Unveils New Aura Collection THC Fizz Tablets
The innovative, lemon-flavored fast-acting tablets provide a quick, uplifting experience, perfect for enhancing social moments or relaxing at home. SAN DIEGO, CA / ACCESS Newswire / February 5, 2025 /...
CV Sciences, Inc. Enters Into Definitive Agreement to Acquire Extract Labs
SAN DIEGO , Nov. 21, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and o...
CV Sciences Earnings Call Transcript: Q3 2024
Q3 2024 revenue held steady at $3.9M with a 46% gross margin, despite regulatory headwinds and a competitive market. Recent acquisitions and new product launches are expected to drive growth and positive cash flow in 2025.
CV Sciences, Inc. Reports Third Quarter 2024 Financial Results
SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and o...